Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell lines by unknown
Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human
cancer cell lines
Hanna Piotrowska • Malgorzata Kucinska •
Marek Murias
Received: 2 June 2013 / Accepted: 10 July 2013 / Published online: 20 July 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract The expression of P450 enzymes and antioxi-
dative enzymes in tumour tissue can have a major impact on
the responsiveness of tumours to cancer chemotherapeutic
drugs, therefore such information may be very precious
when experiments are designed. The compressive informa-
tion, concerning the expression of drug metabolism enzymes
or antioxidative enzymes is still lacking, therefore in this
study the expression of CYP1A1, CYP1B1 and mitochon-
drial superoxide dismutase MnSOD (both mRNA and pro-
tein) in a panel of eight commonly used cancer cell lines,
representing four tumour tissues was assayed. In the study
two ovarian cancer cell lines A2780 and SKOV-3, two
colorectal cancer LOVO and DLD-1, two breast cancer
derived MCF-7 and MDA-MB-231 and two cervical cancer
cell lines HeLa and C33A were employed. The relatively
high expression of all assayed enzymes was shown in MDA-
MB-231 breast cancer cells, lack of cancer cell specific
CYP1B1 protein was discovered in LOVO colorectal cells.
In order to test possible correlation between expression of
CYP1A1, CYP1B1 and MnSOD and modulators of their
activity, cytotoxicity of resveratrol and its promising
hydroxylated analogue 3,30,4,40,5,50-trans-hexahydroxy-
stilbene against cell lines used in experiment was assayed.
The relatively high correlation was found between IC50
values calculated for 3,30,4,40,5,50-trans-hexahydroxystil-
bene and expression of MnSOD (r = 0.6562).
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Abbreviations
A2780 Human ovarian carcinoma cell line
AP-1 Activator protein 1
ATCC American Type Culture Collection
C33A Human cervical carcinoma
CYP Cytochrome P450
DLD-1 Human colon adenocarcinoma cell
line
DMEM Dulbecco’s modified Eagle medium
ECACC European Collection of Cell Cultures
FBS Foetal bovine seum
GAPDH Glyceraldehyde 3-phosphate
dehydrogenase
HeLa Human cervix epitheloid carcinoma
cell line
HRP Horseradish peroxidase
LoVo Human colon adenocarcinoma cell
line
M-MVL Moloney murine leukaemia virus
M12 3,30,4,40,5,50-trans-
Hexahydroxystilbene
MCF-7 Human Caucasian breast
adenocarcinoma
MDA-MB-231 Human Caucasian breast
adenocarcinoma
MnSOD Mitochondrial superoxide dismutase
MRPL19 Mitochondrial ribosomal protein L19
OD Optical density
OVCAR-3 Human ovarian carcinoma cell line
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PAHs Polycyclic aromatic hydrocarbons
RA Relative abundance
RQ-PCR Real time quantitative PCR
SDS Sodium dodecyl sulphate
SKOV-3 Human Caucasian adenocarcinoma
cell line
CuZnSOD (SOD1) Cytosolic superoxide dismutase
MnSOD (SOD2) Mitochondrial superoxide dismutase
SOD3 Extracellular superoxide dismutase
Introduction
A cancer cell culture has been used as a valuable tool for
discovery and development of new anticancer drugs for
decades. They are used for academic, clinical and industrial
research. Although, the most commonly used cell lines were
applied in experiments described in thousands of papers,
even the most important cell culture collections do not pro-
vide compressive information describing their biological
properties like, e.g. the expression of drug metabolizing
enzymes, drug transporters, receptors or antioxidative
enzymes. Only few experimental papers describing and
comparing the expression and/or activity of crucial for can-
cer cell enzymes and factors have been published so far, e.g.
in a panel of cancer cell lines activity of P450 enzyme was
described by Yu et al. [1], microRNA expression profiles
were presented by Blower et al. [2], global microRNA
analysis was performed by Solkilde et al. [3], while expres-
sion of nuclear receptors was described by Holbeck et al. [4].
Compresive analysis of p53 status in cancer cell lines was
provided by Berglind et al. [5] using UMD_p53 database
available on http://p53.free.fr.
Since the expression of P450 enzymes and antioxidative
enzymes in tumour tissue can have a major impact on the
responsiveness of tumours to cancer chemotherapeutic
drugs, such information may be very precious when
experiments are designed. Information regarding expres-
sion of key drug metabolizing enzymes and antioxidative
enzymes may be also useful when prodrugs activated by
cellular metabolic systems are prepared [6–9].
P450 cytochromes are enzymes which catalyse Phase-I
metabolism reactions. These family haem-containing enzymes
catalyse C-, N- and S-oxidation and dealkylation reactions of
both xenobiotics and endobiotics. P450 1A1 (CYP1A1) is,
from a pharmacological point of view, one of the most
important members of the CYP family. CYP1A1 participates
in the metabolism of a large number of xenobiotics, as well as a
small number of endogenous substrates. CYP1A1 is respon-
sible for the metabolism of various drugs, food components,
and environmental contaminants. At the same time hydrox-
ylation at a vacant position of an aromatic ring belongs to the
most important reactions catalysed by this enzyme. This
reaction is believed to be a critical step for the initiation of
carcinogenesis, through the formation of highly reactive con-
version products that can cause oncogenic and teratogenic
mutations in experimental animals and humans [10, 11].
Another interesting member of the CYP1 subfamily is
P450 1B1 (CYP1B1) cytochrome which is, similarly to
CYP1A1, involved in the metabolism of xenobiotics and
endobiotics. Similarly to CYP1A1, CYP1B1 activates
several environmental mutagens, e.g. polycyclic aromatic
hydrocarbons (PAHs), heterocyclic amines and aromatic
amines [6]. CYP1B1 also catalyses the 4-hydroxylation of
estrogens considered to be an important step in hormonal
carcinogenesis [6]. Human CYP1B1 protein was detected
in a variety of tumours but could not be detected in adja-
cent to normal tissues, where only mRNA was detected.
This suggests that CYP1B1 could activate anticancer
agents specifically in the cancer cells. The range of thera-
peutic strategies including CYP1B1-activated prodrugs as
well as CYP1B1 inhibitors are currently tested [8].
The redox cycling of polyhydroxylated compounds cat-
alysed by CYP1A1 and CYP1B1 may result in generation of
superoxide radicals. Superoxide radical (O2
-) plays a cen-
tral role in oxidative stress and impacts on the production of a
plethora of other reactive oxygen species. The cellular and
extracellular level of O2
- is therefore controlled by the
family of very efficient enzymes belonging to the superoxide
dismutase (SOD) family. Cu, ZnSOD (SOD1) is located in
cytosol, MnSOD (SOD2) is located in the mitochondrial
matrix, while SOD3 is located in extracellular space [12, 13].
These enzymes catalyse the dismutation (disproportion-
ation) of O2
- to hydrogen peroxide and molecular oxygen
and are essential to protect aerobic life from the toxic effects
of oxygen [12, 13]. Some studies reported that MnSOD
expression is elevated in cancer cells compared to normal
tissue, including gastric and oesophageal [14, 15], colorectal
[16], prostate [17] and lung cancer [18]. Moreover, MnSOD
was shown in several reports to exert significant effect on
growth and survival of cancer cells, for instance, changes in
MnSOD levels in the cell affect the transcriptional activity of
activator protein-1 (AP-1), dramatically increasing cells
proliferation [19, 20]. It was reported by some authors that
MnSOD overexpression may suprese tumour growth [21];
on the other hand, significant association between increased
MnSOD activity and poor prognosis in cancer can be
attributed to alterations in cancer cell migratory and invasive
capacity [22]. Some reports describe MnSOD-p53 interac-
tions [23–30]. Our own results suggest that ROS-generating
agents may cause p53-mediated MnSOD downregulation
and lead to induction of p53-transcriptional functions, which
subsequently lead to the activation of mitochondrial driven
apoptotic processes. MnSOD is therefore believed a key
enzyme involved in the establishment of the cellular redox
environment and controlling the biological status of cells.
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Inhibition of CYP1 isoenzymes by resveratrol and
methoxy- hydroxy- as well as thiomethylstilbenes was
shown in several in vitro models [31–37]. This project is
kind of pre-study preceding broader project aiming to
evaluate relationship between CYP1A1, CYP1B1 and
MnSOD and their effect on cytotoxic activity of resveratrol
and its higher hydroxylated analogues. Therefore, as a first
step we needed to screen expression of these enzymes in a
panel of cancer cells and find possible correlation between




bene (M12), was synthesized as described previously [38].
The RQ-PCR probes were provided by Roche (Mannheim,
Germany). Probe numbers: 59, 61, 27, 60 and 23 were used
for CYP1A1, CYP1B1, MnSOD, GADPH, and MRPL19
detection, respectively. The monoclonal antibodies were
purchased from Santa Cruz Biotechnology (Dallas, TX
USA). All other reagents used in experiments (including
resveratrol) were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
Cell culture
The cancer cell lines used in the experiment were pur-
chased from the European Type Culture Collection
(Sigma-Aldrich Co., St. Louis, MO, USA). The cell lines
are listed in Table 1. The cells were maintained in phenol
red-free DMEM medium supplemented with 10 % foetal
bovine serum (FBS), 2 mM glutamine, penicillin (100 U/
ml), and streptomycin (0.1 mg/ml). The cells were culti-
vated under standard conditions at 37 C in a humidified
atmosphere containing 5 % CO2 and 95 % air. For RNA
isolation and western blot analysis the cells were seeded in
a 6-well plates at a density of 1 9 106 cells per well. All
the cell culture chemicals were obtained from Sigma-
Aldrich Co. St. Louis, MO, while all the cell culture con-
sumables were provided by BD Falcon.
Real-time quantitative PCR (RTq-PCR) analysis
Total RNA was isolated according to the method of
Chomczynski and Sacchi [39].The RNA concentration was
quantified by measuring the optical density (OD) at
260 nm and their integrity was confirmed by denaturing
agarose gel electrophoresis. RNA samples were treated
with DNAse I and reverse-transcribed into cDNA using
oligo-dT primers. Reverse transcription was performed
using M-MLV Reverse Transcriptase (Invitrogen, Carls-
bad, CA, USA) according to manufacturer instructions.
RQ-PCR was conducted in the Light Cycler real-time
PCR detection system Roche Diagnostics GmbH, (Mann-
heim, Germany) using a LightCycler 480 Probes Master
kit. Target cDNA was quantified using the relative quan-
tification method. The quantity of CYP1A1, CYP1B1 and
MnSOD in each sample was standardized by GAPDH and
MRPL19 (Table 2). For RTq-PCR analysis of CYP1A1,
CYP1B1 and MnSOD mRNA expression, 1 ll of total
(20 ll) cDNA solution was added to the mixture of the
LightCycler 480 Probes Master kit (Roche, Mannheim,
Germany), primers and probes for CYP1A1, CYP1B1 and
MnSOD respectively. In case of negative control, cDNA
was not added.
SDS-PAGE and western blot analysis
The cells were grown in 6 well plates. The cells were
collected when they were 60 % confluent and dissolved in
a RIPA buffer with proteinase inhibitors (30 min on ice)
and centrifuged. The obtained supernatant was used for
electrophoresis, protein concentration in supernatant was
determined using Qubit fluorometer (Invitrogen) and
Quant-iTTM Protein Assay Kit (Invitrogen, Burlington,
Ontario,Canada). For electrophoresis, 30 lg of protein
were resuspended in sample buffer and separated on 10 %
Tris–glycine gel using SDS-PAGE. Gel proteins were
transferred to nitrocellulose, which was blocked with 5 %
milk in Tris buffered saline/Tween. Immunodetection was
performed with rabbit polyclonal anti-CYP1A1 Ab (sc-
20772), rabbit polyclonal anti-CYP1B1 Ab (sc-32882),
anti-MnSOD Ab (sc-30080) followed by incubation with
goat anti-rabbit HRP- conjugated Ab (sc-2004). The
membranes were also incubated with anti-actin HRP con-
jugated Ab (sc-1616) to ensure equal protein loading of the
lanes. Bands were revealed using SuperSignal West Femto
maximum sensitivity substrate Pierce Biotechnology Inc.
(Rockford, IL, USA). Densitometric quantification of band
intensity was measured using ImageJ 1.46 software (NIH,
USA) and was normalised relatively to the band intensity
of the b-actin loading control.
Cytotoxicity study
As recent data showed the MTT-reducing activity can be
increased by the polyphenolic antioxidant resveratrol
without a corresponding increase in the number of living
cells, therefore a protein determination assay was used for
the cytotoxicity experiments adapted from Seibert et al.
[40]. Briefly, the cells were detached using trypsin, counted
using Casy-1 cell counter (Scharfe System, Reutlingen
Germany), and seeded into 96 well plates at the density of
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10,000 cells/100 lL/well. Cells were allowed to attach
overnight and incubated for 24 h with resveratrol and
3,30,4,40,5,50-trans-hexahydroxystilbene in concentrations
ranging from 1.5 to 100 lM in six replicates. DMSO was
used as a control, and the concentration in medium did not
exceed 0.1 %.Two groups of six wells receiving 0.1 %
DMSO served as a control. After incubation, the medium
was aspirated and the cell layers were washed three times
with phosphate buffered saline (PBS). Cells were lysed by
incubation with 0.5 N NaOH for 45 min at 37 C. Protein
content was determined Bio-Rad Protein Assay Kit (Bio-
Rad Hercules, USA) modified for microtiter plates. Bovine
serum albumin (BSA) (1.5–24 lg/well) was used to
determine the standard curve. Absorption at 750 nm was
read with a microtiter plate photometer (ELX800, Bio-
TEK). The protein content of culture wells was compared
to the mean protein content of the control cultures (12-
wells per plate) and expressed as percentage of control.
Experiments were replicated at least 2 times with cultures
of different passages. The IC50 values were determined
from semilogarithmic plots of the mean concentration-
effect relationships.
Table 1 Cancer cell lines used in experiment








Derived from human colorectal adenocarcinoma.
The cells have been used in the study of polar
solvents on cell characteristics
Epithelial/adherent Mutated [49, 50]
LOVO Human colon
adenocarcinoma/modal
no. 49, (2n = 46)
Derived from a metastatic tumour in the left
supraclavicular region of a 56-year-old male
with adenocarcinoma of the colon. The cells
produce carcino embryonic antigen (CEA)
Epithelial/adherent Wt [49]
A2780 Human ovarian carcinoma/
not specified
The A2780 human ovarian cancer cell line was
established from tumour tissue from an
untreated patient. Cells grow as a monolayer
and in suspension in spinner cultures
Epithelial/adherent Wt [51]




Derived from the ascitic fluid from a 64-year-old
Caucasian female with an ovarian tumour.
Forms moderately well-differentiated
adenocarcinoma consistent with ovarian
primary cells
Epithelial/adherent Wt [51]




Established from the pleural effusion from a
69-year-old Caucasian female suffering from a
breast adenocarcinoma. Cells exhibit some
features of differentiated mammary epithelium
including oestradiol synthesis and formation of
domes. Cells may carry B or C type retrovirus
and are considered to represent a category 2
pathogen (P2 containment). Cells express both
the wild type and variant oestrogen receptors as






no.’s 62 and 64, near
triploid
Isolated from pleural effusions of a breast cancer
patient
Epithelial/adherent Mutated [53]
HeLa Human cervix epitheloid
carcinoma/modal no.’s 62
and 64, near triploid
Derived from a cervical carcinoma from a
31-year-old female. This was the first
aneuploid line derived from human tissue
maintained in continuous cell culture.
Susceptible to Poliovirus type I and adenovirus
type 3. Identified as a contaminant in many
other cell lines. The cells should be handled
under laboratory containment level 2.
Ethnicity: Black
Epithelial/adherent Wt [54]
C-33A Human Caucasian cervical
carcinoma/hypodiploid
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Statistical analysis
One-way ANOVA followed by Dunnett’s multiple com-
parisons test was performed using GraphPad Prism version
6.02 for Windows, GraphPad Software, La Jolla California
USA, www.graphpad.com.
Results
In this study expression of cytochrome P450 (CYP) iso-
forms CYP1A1, CYP1B1 as well as MnSOD in 8 cell lines
representing 4 tumuor tissues is presented. In the tested
cells the highest MnSOD mRNA expression was found in
MDA-MB-231 cells (RA = 1.79 ± 0.14), while the lowest
expression was found in MCF-7 (RA = 0.34 ± 0.09),
C33A (RA = 0.32 ± 0.07) and A2780
(RA = 0.31 ± 0.02) cell lines. These results were in
agreement with MnSOD protein level measured using the
western blot technique. The only exception was LOVO cell
line. In this colorectal cell line the level of MnSOD protein
was relatively high when compared with mRNA (Fig. 1).
The highest level of CYP1A1 mRNA was found in both
breast cancer cell lines: MCF-7 (RA = 2.04 ± 0.43) and
MDA-MB-231(RA = 1.86 ± 0.30) used in our screening;
similarly the highest level of CYP1A1 protein was found in
these lines (Fig. 2). The most interesting results were
obtained for CYP1B1; the highest level of CYP1B1 protein
was again measured in HeLa and SKOV-3 cells followed
by MDA-MB-231 cells. CYP1B1 mRNA and protein level
in LOVO cells can be presented as the most interesting
results obtained in our study. The CYP1B1 mRNA level
was very low (RA = 0.05 ± 0.01) while CYP1B1 protein
was not present in colorectal LOVO cancer cells (Fig. 3).
Detailed statistical analysis is provided in supplementary
materials (Tables 1s, 2s, 3s).
In order to test possible relationship between the
expression of CYP1A1, CYP1B1 and MnSOD and
cytotoxicity of compounds tested in our laboratory we were
able to analyse the relationship between cytotoxic activity
of resveratrol (3,40,5-trans-hydroxystilbene) and
3,30,4,40,5,50-trans-hexahydroxystilbene (M12). The IC50
values obtained in cytotoxicity studies are presented in
Table 3. The relatively high correlation (r2 = 0.6562)
between expression of MnSOD and cytotoxicity of M12
was found and presented in Fig. 4, all other relationships
are presented in Fig. 1s.
Fig. 1 Gene and protein expression of MnSOD in tested cell lines.
A RTq-PCR analyses; relative abundance of MnSOD mRNAs,
B Western blot analyses of MnSOD bands, the bands of b-actin were
measured to normalise the results. Densitometric quantification of
the corresponding bands was performed using ImageJ 1.45 software.
All results are presented and mean ± SD from three experiments.
Detailed statistical analysis is provided in supplementary materials
Table 2 Oligonucleotide
sequences used for RTq-PCR
analysis






CYP1A1 50 ggggcgttgtgtctttgtaa 30 59 NM_000499.3 64
50 tgggttgacccatagcttct 30
CYP1B1 50 ggcattagagtcaactacacaaagc 30 61 NM_000104.3 67
50 gaatggcaagtgccaaaaa 30
SOD-2 50 gcactagcagcatgttgagc 30 27 NM_001024466.1 76
50 gagcccagataccccaaaac 30
GAPDH 50 ctctgctcctcctgttcgac 30 60 NM_002046.3 112
50 acgaccaaatccgttgactc 30
MRPL19 50 caattacacgcgtgaaccac 30 23 NM_014763.3 62
50 ggtggagtaggcacattgaaa 30
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Discussion
Cancer cell lines are extensively used for various experi-
ments in scientific laboratories worldwide. Although, a
plethora of data is generated every day in the field of
cancer cells research, there is a need for systematization
and collation of available information about their proper-
ties like expression of enzymes, receptors or transcription
factors. The expression of drug metabolizing and antioxi-
dative enzymes is a crucial parameter for designing of
anticancer drugs [41, 42]. Differences in the expression of
drug metabolizing enzymes and drug transporters in cancer
cells, were shown in several reports and were used to
explain diverse effect of several natural products and
anticancer agents against different cancer cell lines. For
instance, it was shown that the expression of organic anion-
transporting polypeptides 1B1 and 1B3 in ovarian cancer
OVCAR-3 and SKOV-3 cells may modulate paclitaxel
disposition during therapy [43], while the expression of
sulfotransferase 1A1 may modify growth of breast cancer
cells incubated with resveratrol [44]. The activation of the
natural product eupatorin, which is attributed to CYP1A1
expression in MDA-MB-486 cells, but not normal MCF-
10A cells, was described by Androutsopoulos and
coworkers [45]. It was also suggested that different
CYP1B1 expression patterns in ovarian cell lines A2780
and SKOV-3 may affect their sensitivity to cytotoxic
activity of 3,4,40,5-tetramethoxystilbene (DMU-212) [46].
In our opinion data presented in this paper may be very
helpful in designing similar experiments. On the other
hand, this information may be also useful in designing
experiments employing transfection of these cells with
siRNA or cDNA targeting CYP1A1, CYP1B1 and
Fig. 2 Gene and protein expression of CYP1A1 in tested cell lines.
A RTq-PCR analyses; relative abundance of CYP1A1 mRNAs,
B Western blot analyses of CYP1A1 bands, the bands of b-actin were
measured to normalise the results. Densitometric quantification of the
corresponding bands was performed using ImageJ 1.45 software. All
results are presented and mean ± SD from three experiments.
Detailed statistical analysis is provided in supplementary materials
Fig. 3 Gene and protein expression of CYP1B1 in tested cell lines.
A RTq-PCR analyses; relative abundance of CYP1B1 mRNAs,
B Western blot analyses of CYP1B1 bands, the bands of b-actin were
measured to normalise the results. Densitometric quantification of the
corresponding bands was performed using ImageJ 1.45 software. All
results are presented and mean ± SD from three experiments.
Detailed statistical analysis is provided in supplementary materials
Table 3 Cytotoxic activity of resveratrol and M12 against cell lines
used in experiment
Cell line Resveratrol IC50 (lM) M12 IC50 (lM)
MCF-7 49.7 ± 9.4 25.6 ± 6.1
MDA-MB-231 38.1 ± 5.4 127.8 ± 1.6
DLD-1 42.7 ± 1.1 25.3 ± 2.6
SKOV-3 44.4 ± 9.8 94.4 ± 1.5
LOVO 57.0 ± 8.4 36.7 ± 4.0
Hela 53.9 ± 1.3 35.2 ± 5.8
A2780 35.4 ± 2.5 18.4 ± 0.9
C33A 72.5 ± 4.7 11.6 ± 2.5
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MnSOD. For example, such experiments were used for
explanation of activation of 2-amino-1-methyl-6-phenyli-
midazo[4,5-b]pyridine by CYP1A1 on mutagenesis and
DNA damage in CHO cells [47], while experiments
employing CYP1B1 transfected cells were used to explain
its role in activation of docetaxel [48]. As it was shown in
our cytotoxicity study, the correlations between the P450 or
MnSOD activities and the patterns of toxicity of anticancer
agents may also aid in the design of further experiments to
evaluate new hypotheses regarding the role of P450 and
MnSOD enzymes in the metabolism of selected anticancer
agents. The most interesting results of our study showed,
that level of MnSOD expression in cancer cells may
modulate cytotoxic effect exerted by superoxide generating
compounds like, e.g. M12, this hypothesis, however,
should be further evaluated using cells stably transfected
with MnSOD.
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